Activation of MC1R with BMS-470539 attenuates neuroinflammation via cAMP/PKA/Nurr1 pathway after neonatal hypoxic-ischemic brain injury in rats.
Yu S, Doycheva DM, Gamdzyk M, Yang Y, Lenahan C, Li G, Li D, Lian L, Tang J, Lu J, Zhang JH
Activating the MC1R receptor with BMS-470539 reduced brain damage and improved brain function in rats after oxygen deprivation at birth, likely by boosting the Nurr1 protein through a specific signaling pathway. This suggests a potential treatment strategy for infants with hypoxic-ischemic brain injury.
- MC1R activation reduces brain damage after oxygen loss in newborn rats
- BMS-470539 improves movement and brain function long-term
- The effect works through the cAMP/PKA/Nurr1 pathway
- Blocking Nurr1 or MC1R removes the protective benefit
- Intranasal delivery shows promise for future therapies
GDNF Therapy: Can We Make It Work?
Björklund A
GDNF and NRTN therapies may help Parkinson's patients by restoring signaling in dopamine neurons, especially if dosing is improved and the body's natural Nurr1 factor is engaged. New evidence shows that in Parkinson's brains, the key receptor for these therapies is severely reduced in damaged neurons, but some neurons still retain a low level of function. In a few patients treated years earlier with NRTN gene therapy, the receptor was restored, suggesting long-term potential.
- GDNF/NRTN therapy may work if dosing is fixed
- Key receptor Ret is lost in Parkinson's neurons
- NRTN therapy may restore Ret and signaling
- Nurr1 protein likely helps activate this repair
- Some patients show lasting recovery after therapy
Lipoic acid alleviates LPS‑evoked PC12 cell damage by targeting p53 and inactivating the NF‑κB pathway.
Mao J, Gao H, Bai W, Zeng H, Ren Y, Liu Y, Yang X
Lipoic acid reduces inflammation and cell damage in a lab model of Parkinson's disease by blocking the p53 and NF-κB pathways, which may help protect nerve cells. This suggests lipoic acid could have potential as a treatment to reduce brain inflammation in neurodegenerative conditions.
- Lipoic acid reduces brain cell damage in a Parkinson's model
- It blocks harmful inflammation and cell death pathways
- It restores levels of key brain proteins like Nurr1 and TH
- The effect depends on suppressing p53 and NF-κB activity
- Findings support further study of lipoic acid for brain health
Expression Profiling of Rectal Biopsies Suggests Altered Enteric Neuropathological Traits in Parkinson's Disease Patients.
Cossais F, Schaeffer E, Heinzel S, Zimmermann J, Niesler B, Röth R, Rappold G, Scharf A, Zorenkov D, Lange C, Barrenschee M, Margraf NG, Ellrichmann M, Berg D, Böttner M, Wedel T
Parkinson's disease patients show significant changes in gene expression related to nerve function, inflammation, and energy production in their rectal tissue, suggesting widespread gut nerve damage in many people with Parkinson's.
- 22 genes linked to nerve and immune function are altered in PD patients
- Changes suggest gut nerves are affected in most Parkinson's patients
- Rectal biopsies reveal early signs of intestinal neuropathy
- These findings may help track Parkinson's progression
- Could inform future treatments targeting gut health
Expression of Transcription Factors in CD4 + T Cells as Potential Biomarkers of Motor Complications in Parkinson's Disease.
Contaldi E, Magistrelli L, Milner AV, Cosentino M, Marino F, Comi C
People with Parkinson's disease who do not have motor complications have higher levels of the NR4A2 gene in their immune cells, while those with complications have higher levels of another gene called STAT6. These differences suggest NR4A2 and STAT6 could help predict motor complications in Parkinson's.
- NR4A2 is higher in Parkinson's patients without motor issues
- STAT6 is higher in Parkinson's patients with motor complications
- NR4A2 and STAT6 may serve as blood-based biomarkers
- These genes could help predict motor complications early
- Findings come from immune cells in Parkinson's patients
Research on developing drugs for Parkinson's disease.
Zhang CL, Han QW, Chen NH, Yuan YH
This review discusses new drug targets for Parkinson's disease, including Nurr1, which is the same gene affected in NR4A2-related syndrome. It highlights promising research beyond dopamine replacement that could lead to treatments addressing the root causes of neurodegeneration.
- Nurr1 is a key target for new Parkinson's drugs
- NR4A2 and Nurr1 are the same protein
- Research aims to move beyond dopamine therapy
- New treatments may slow or stop disease progression
NURR1 Alterations in Perinatal Stress: A First Step towards Late-Onset Diseases? A Narrative Review.
Bordoni L, Petracci I, Calleja-Agius J, Lalor JG, Gabbianelli R
Changes in the NURR1 protein during early development, caused by maternal stress or environmental toxins, may disrupt brain development and increase the risk of neurological and psychiatric conditions later in life. This suggests NURR1 could be a target for early intervention to prevent long-term health issues.
- NURR1 is vital for brain development and stress response
- Maternal health issues can alter NURR1 in the fetus
- Early disruptions may lead to lifelong neurological risks
- NURR1 may guide future treatments or early detection
Assessment of NR4A Ligands That Directly Bind and Modulate the Orphan Nuclear Receptor Nurr1.
Munoz-Tello P, Lin H, Khan P, de Vera IMS, Kamenecka TM, Kojetin DJ
Some drugs that were thought to affect Nurr1, a protein linked to neurological disorders, actually bind directly to it, while others do not. These findings help identify which compounds are likely to work on Nurr1 and which may have unrelated effects, guiding future drug development.
- Amodiaquine, chloroquine, and cytosporone B bind directly to Nurr1
- Many other tested compounds do not bind Nurr1
- Some compounds affect gene activity in ways unrelated to Nurr1
- This helps focus drug development on truly effective Nurr1-targeting molecules
- Results support better design of future therapies for NR4A2-related conditions
Identification of Pathways and Key Genes in Venous Remodeling After Arteriovenous Fistula by Bioinformatics Analysis.
Jie K, Feng W, Boxiang Z, Maofeng G, Jianbin Z, Zhaoxuan L, Yangyi Z, Liang C, Haobo S, Wensheng L, Guoping C, Jianping G, Xu H, Jianyan W
This study identifies NR4A2 as a key gene involved in vein changes after arteriovenous fistula creation, a common procedure for dialysis. The gene's increased activity may drive structural and functional changes in veins, potentially affecting fistula success. These findings could help develop treatments to improve fistula maturation and reduce failure.
- NR4A2 is significantly upregulated in veins after fistula formation
- NR4A2 may play a central role in venous remodeling
- Increased NR4A2 levels were confirmed in human tissue samples
- The findings point to potential new treatment targets for fistula failure
- This provides insight into the molecular basis of vein adaptation
DNA methylation and psychotherapy response in trauma-exposed men with appetitive aggression.
Xulu KR, Womersley JS, Sommer J, Hinsberger M, Elbert T, Weierstall R, Kaminer D, Malan-Müller S, Seedat S, Hemmings SMJ
Psychotherapy reduced PTSD and appetitive aggression symptoms in trauma-exposed men, with increased methylation of NR4A2—a gene linked to dopamine signaling—associated with better treatment outcomes. Methylation changes in other genes related to brain function and energy production also correlated with symptom improvement.
- NR4A2 methylation increased with better PTSD outcomes
- Psychotherapy reduced both PTSD and aggression symptoms
- Epigenetic changes in brain-related genes tracked with symptom improvement
- Mitochondrial gene methylation linked to appetitive aggression
- Findings suggest therapy may work through gene regulation
Effect of selected bisphenol derivatives on nuclear receptor expression in ovarian cell line COV434.
Mlynarcikova AB, Scsukova S
Bisphenol analogs BPAF and BPS increased the mRNA levels of NURR1 and PPARD in ovarian cells at high concentrations after 48 hours, but BPA did not. No changes in cell viability or other nuclear receptors were observed.
- BPAF and BPS raised NURR1 and PPARD mRNA at high doses
- No effect on cell survival or other nuclear receptors
- Changes seen only after 48 hours and at 10⁻⁵ M
- NURR1 is relevant to NR4A2-related syndrome
- Findings may inform environmental exposure risks
Complex regulation of orphan nuclear receptor Nur77 (Nr4a1) transcriptional activity by SUMO2 and PIASγ.
Dodat F, Cotnoir-White D, Dianati E, Vallet A, Mader S, Lévesque D
Nur77, a key protein involved in brain function and metabolism, is regulated by SUMO2 and PIASγ, which reduce its activity. Mutations at specific sites (K102 and K577) alter how Nur77 functions, with K577 playing a major role in this regulation. These findings reveal new control points that could influence Nur77 activity in disease.
- SUMO2 and PIASγ reduce Nur77 activity
- K577 mutation increases Nur77 activity
- K102 mutation reduces Nur77 activity
- These sites are critical for regulation
- Findings may inform future therapies
The nuclear receptor 4A family members: mediators in human disease and autophagy.
Chen L, Fan F, Wu L, Zhao Y
NR4A2 (Nurr1) is a key gene regulator involved in brain development and function, and its dysfunction is linked to neurological disorders. The NR4A family, including NR4A2, plays a critical role in controlling autophagy—a cellular cleanup process—whose imbalance may contribute to disease. Understanding these pathways could lead to new treatments for NR4A2-related conditions.
- NR4A2 regulates brain development and function
- NR4A2 dysfunction is tied to neurological disorders
- NR4A family controls autophagy in cells
- Autophagy imbalance may drive disease
- Targeting NR4A pathways could lead to new therapies
Direct conversion of human fibroblasts into dopaminergic neuron-like cells using small molecules and protein factors.
Qin H, Zhao AD, Sun ML, Ma K, Fu XB
This study shows that human skin cells can be directly turned into dopamine-producing brain cells using a mix of small molecules and proteins, without needing genetic engineering or intermediate stem cell stages. The resulting cells show key features of real neurons and can fire electrical signals, making them a promising source for future Parkinson's disease treatments.
- Human skin cells converted to dopamine neurons without genetic changes
- Conversion uses small molecules and proteins, not viruses or gene editing
- Resulting cells show neuron-like structure and electrical activity
- No stem cell stage involved, making the process faster and safer
- Potential for cell therapy in Parkinson's disease and related disorders
Gene expression in the epileptic (EL) mouse hippocampus.
Lee TS, Li AY, Rapuano A, Mantis J, Eid T, Seyfried TN, de Lanerolle NC
In the EL mouse model of epilepsy, brain changes linked to seizures occur without neuron loss, but with activated astrocytes and microglia. These glial cells contribute to hyperexcitability by reducing inhibition and impairing glutamate clearance, while gene changes suggest both neuroprotection and increased seizure risk.
- No neuron loss, but glial activation drives seizures
- Astrocytes fail to clear glutamate due to low glutamine synthetase
- Microglia may remove GABAergic synapses, reducing inhibition
- Gene changes include upregulated BDNF and NR4A2, linked to excitability
- HSPs and chaperones may protect neurons despite stress
Parkinsonism in children: Clinical classification and etiological spectrum.
Leuzzi V, Nardecchia F, Pons R, Galosi S
Children with parkinsonism often have genetic causes, and the condition can appear in different forms depending on when symptoms start and what underlying genetic or developmental issues are present. Some forms are linked to specific gene defects like NR4A2, which affects brain development and can lead to early-onset movement disorders. Understanding these subtypes helps guide diagnosis and may point to future treatments.
- NR4A2 mutations are linked to early-onset parkinsonism in children
- Parkinsonism in kids often stems from genetic defects affecting brain development
- Specific subtypes include developmental and degenerative forms tied to gene mutations
- Some neurodevelopmental disorders can later show neurodegenerative features
- Multiple genetic changes may combine to cause childhood parkinsonism
Differential Expression of microRNA Profiles and Wnt Signals in Stem Cell-Derived Exosomes During Dopaminergic Neuron Differentiation.
Jin T, Gu J, Xia H, Chen H, Xu X, Li Z, Yue Y, Gui Y
Exosomes from stem cells that are turning into dopamine-producing neurons carry specific microRNAs that help guide this process. These exosomes boost the creation of dopamine neurons from other stem cells, suggesting they could be used to improve treatments for conditions like NR4A2-related syndrome.
- Exosomes carry microRNAs that guide dopamine neuron development
- NR4A2 levels rise in exosomes during differentiation
- Stem cell exosomes increase dopamine neuron production by twofold
- Wnt and other key brain pathways are influenced by exosomal miRNAs
- These exosomes may help repair or replace damaged dopamine neurons
Transgenerational modification of dopaminergic dysfunctions induced by maternal immune activation.
Weber-Stadlbauer U, Richetto J, Zwamborn RAJ, Slieker RC, Meyer U
Maternal immune activation in mice leads to opposite changes in dopamine function across generations: the first generation has overactive dopamine systems, while later generations show reduced dopamine activity. These changes are linked to lasting epigenetic modifications in the Nurr1 gene, which is critical for dopamine neuron development and function.
- First-generation offspring show increased dopamine activity
- Later generations have reduced dopamine responses
- Epigenetic changes in Nurr1 gene are found in sperm and brain
- Nurr1 is essential for healthy dopamine neurons
- Male germline epigenetics may pass effects to future generations
Human Mesenchymal Stromal Cells Unveil an Unexpected Differentiation Potential toward the Dopaminergic Neuronal Lineage.
Gaggi G, Di Credico A, Izzicupo P, Alviano F, Di Mauro M, Di Baldassarre A, Ghinassi B
Human mesenchymal stromal cells from the amniochorionic membrane can be reprogrammed into dopamine-producing neurons, suggesting a potential source for cell replacement therapy in conditions like Parkinson’s disease. These cells express key genes linked to pluripotency and can develop into functional dopaminergic neurons in the lab.
- hFM-MSCs express pluripotency genes like OCT4 and NANOG
- They can be directed to become dopaminergic neurons
- Generated cells express TH, DAT, and Nurr1—key markers of dopamine neurons
- This offers a non-pluripotent, ethically favorable cell source for therapy
- Potential for treating dopaminergic neuron loss in neurodegenerative diseases
The Extracts of Human Fetal Brain Induce the Differentiation of Human Umbilical Cord Mesenchymal Stem Cells into Dopaminergic Neuron Containing Cells.
Li Y, Yang J, Li M, Zhang X, Du J, Zhao X, Xu Z, Lin J
Extracts from human fetal brain tissue can turn human umbilical cord stem cells into cells that produce dopamine, a key brain chemical missing in Parkinson's disease. This method creates a potential new source of dopamine-producing cells for treating neurodegenerative conditions.
- Fetal brain extracts turn stem cells into dopamine-making cells
- Cells express key markers of dopaminergic neurons
- Potential new cell source for Parkinson's disease treatment
- Method works in lab settings using human stem cells
Carbon Fibers as a New Type of Scaffold for Midbrain Organoid Development.
Tejchman A, Znój A, Chlebanowska P, Frączek-Szczypta A, Majka M
Carbon fiber scaffolds improve the growth and survival of midbrain organoids made from stem cells, leading to better development of dopamine-producing neurons important for studying Parkinson's disease and related conditions.
- Carbon fiber scaffolds support healthier midbrain organoids
- Better survival of dopamine neurons compared to older materials
- Organoids on carbon fibers show improved gene markers for brain development
- This model helps study Parkinson's and other midbrain disorders
- May lead to better drug testing and disease understanding
Analysis of rare variants of autosomal-dominant genes in a Chinese population with sporadic Parkinson's disease.
Zheng R, Jin CY, Chen Y, Ruan Y, Gao T, Lin ZH, Dong JX, Yan YP, Tian J, Pu JL, Zhang BR
Rare variants in autosomal-dominant Parkinson's disease genes, including LRRK2 and NR4A2, are more common in Chinese people with sporadic Parkinson's disease than in controls, suggesting these genes contribute to the disease even without a family history. This supports the idea that genetic testing for these genes may help identify causes in individual cases.
- Rare variants in PD genes are linked to sporadic Parkinson's in Chinese patients
- LRRK2 variants significantly increase Parkinson's risk
- Undetermined variants in NR4A2 and other genes may contribute to disease
- Genetic testing for these genes could be useful in diagnosis
Origin of the Induced Pluripotent Stem Cells Affects Their Differentiation into Dopaminergic Neurons.
Chlebanowska P, Sułkowski M, Skrzypek K, Tejchman A, Muszyńska A, Noroozi R, Majka M
The source of cells used to create induced pluripotent stem cells (iPS cells) can affect how well they turn into dopamine-producing neurons, especially in two-dimensional cultures. This matters for modeling diseases like NR4A2-related syndrome and testing potential treatments.
- Cell source affects dopamine neuron development from iPS cells
- Differences seen in 2D cultures, especially for key genes like NURR1
- Early stages of 3D organoid formation also influenced by cell origin
- Findings impact disease modeling and therapy testing
- Relevance to NR4A2-related conditions is strong
Integrative Analysis of Gene Expression and Regulatory Network Interaction Data Reveals the Protein Kinase C Family of Serine/Threonine Receptors as a Significant Druggable Target for Parkinson's Disease.
Odumpatta R, Arumugam M
This study identifies several key genes, including NR4A2, that are central to Parkinson's disease pathology and may serve as targets for new treatments. The research highlights the protein kinase C family and other regulatory molecules as potential druggable targets, offering insights into disease mechanisms and therapeutic strategies.
- NR4A2 is a hub gene in Parkinson's disease networks
- Protein kinase C family is a promising druggable target
- MYC and miRNAs like miR-7 regulate key PD genes
- SYT1 may serve as a novel biomarker for PD
- Findings reveal molecular pathways involved in PD progression
CD4+ T-cell Transcription Factors in Idiopathic REM Sleep Behavior Disorder and Parkinson's Disease.
De Francesco E, Terzaghi M, Storelli E, Magistrelli L, Comi C, Legnaro M, Mauri M, Marino F, Versino M, Cosentino M
People with idiopathic REM sleep behavior disorder, a strong early sign of Parkinson's disease, have abnormal immune cell activity that closely matches patterns seen in Parkinson's patients, suggesting immune system changes may begin before symptoms appear.
- Immune cells in REM sleep disorder show immune changes like those in Parkinson's
- These changes appear early, possibly before Parkinson's symptoms start
- Specific genes linked to immune regulation are altered in both conditions
- The findings suggest immune system involvement in Parkinson's development
The orphan nuclear receptor Nurr1 is responsive to non-steroidal anti-inflammatory drugs.
Willems S, Kilu W, Ni X, Chaikuad A, Knapp S, Heering J, Merk D
Non-steroidal anti-inflammatory drugs (NSAIDs) can directly affect Nurr1, a key protein involved in NR4A2-related syndrome, by turning it off. This discovery reveals how Nurr1 works and offers new tools to study and potentially treat conditions linked to Nurr1 dysfunction.
- NSAIDs act as inverse agonists, turning off Nurr1 activity
- Nurr1 can recruit different co-regulators depending on the drug
- Different Nurr1 shapes and interactions distinguish activators from blockers
- These findings help identify new ways to target Nurr1 for therapy
- The results provide tools for future drug development for NR4A2 disorders
Nurr1 performs its anti-inflammatory function by regulating RasGRP1 expression in neuro-inflammation.
Oh M, Kim SY, Gil JE, Byun JS, Cha DW, Ku B, Lee W, Kim WK, Oh KJ, Lee EW, Bae KH, Lee SC, Han BS
Nurr1 reduces brain inflammation by controlling the activity of a protein called RasGRP1, which is involved in immune signaling. This discovery reveals a direct link between Nurr1 and inflammation regulation, potentially offering new treatment targets for NR4A2-related conditions.
- Nurr1 controls inflammation by regulating RasGRP1
- RasGRP1 affects key immune signaling pathways
- This mechanism may be relevant to NR4A2-related disorders
- Findings could lead to new anti-inflammatory treatments
Genome-Wide Analysis Identifies NURR1-Controlled Network of New Synapse Formation and Cell Cycle Arrest in Human Neural Stem Cells.
Kim SM, Cho SY, Kim MW, Roh SR, Shin HS, Suh YH, Geum D, Lee MA
NURR1 controls key genes involved in building synapses, guiding neurons, and stopping cell division in human brain stem cells, mirroring how dopamine-producing brain cells develop. This helps explain how NURR1 mutations may disrupt brain development in NR4A2-related syndrome.
- NURR1 regulates genes for synapse formation and neuron movement
- NURR1 stops cell division in brain stem cells
- These processes match how dopamine neurons form in the brain
- Identified genes may explain NR4A2 syndrome symptoms
- Findings come from human neural stem cells, not just animals
Transfer of pathological α-synuclein from neurons to astrocytes via exosomes causes inflammatory responses after METH exposure.
Meng Y, Ding J, Li C, Fan H, He Y, Qiu P
Methamphetamine exposure causes neurons to release exosomes carrying abnormal alpha-synuclein, which are taken up by astrocytes, triggering inflammation. This process involves a drop in Nurr1 levels, a protein linked to NR4A2, suggesting a potential target for reducing brain inflammation.
- Methamphetamine causes neurons to send toxic alpha-synuclein via exosomes
- Astrocytes take up this abnormal protein and become inflamed
- Nurr1 levels drop in astrocytes during this process
- Low Nurr1 may drive inflammation in brain cells
- Boosting Nurr1 could help protect the brain from damage
Weighted gene co-expression network analysis to investigate the key genes implicated in global brain ischemia/reperfusion injury in rats.
Ma D, Qiao J, Qu Q, He F, Chen W, Yu B
This study identifies NR4A2 as one of the key genes downregulated in brain injury from reduced blood flow and restored circulation in rats, suggesting it may play a protective role in brain damage. Other important genes include HSPB1, HMOX1, and HSPA5, which are involved in stress response and inflammation.
- NR4A2 is downregulated in brain ischemia/reperfusion injury
- HSPB1 and HMOX1 are upregulated, indicating stress response
- HSPA5 and HSP90AA1 are central in protein interaction networks
- MYC and HSF1 are key transcription factors in regulatory networks
- miR-22 may regulate genes involved in brain injury
Genetic Architecture and Molecular Neuropathology of Human Cocaine Addiction.
Huggett SB, Stallings MC
This study found that NR4A2 is one of 133 genes with altered expression in the brains of people with cocaine use disorder, suggesting it may play a role in addiction-related brain changes. While NR4A2 was not directly linked to genetic risk for addiction in this study, it is part of a larger network of genes involved in key brain signaling systems like dopamine and GABA.
- NR4A2 is dysregulated in cocaine use disorder brains
- NR4A2 is part of a gene network tied to dopamine and addiction
- Genetic risk for addiction converges on brain and other tissues
- Findings may help explain how addiction affects brain function
PGE1 and PGA1 bind to Nurr1 and activate its transcriptional function.
Rajan S, Jang Y, Kim CH, Kim W, Toh HT, Jeon J, Song B, Serra A, Lescar J, Yoo JY, Beldar S, Ye H, Kang C, Liu XW, Feitosa M, Kim Y, Hwang D, Goh G, Lim KL, Park HM, Lee CH, Oh SF, Petsko GA, Yoon HS, Kim KS
PGE1 and PGA1 are natural molecules that bind to and activate Nurr1, a protein essential for healthy dopamine-producing brain cells. This activation boosts the expression of protective genes and improves movement problems in a mouse model of Parkinson’s disease, suggesting a potential treatment path for NR4A2-related disorders.
- PGE1 and PGA1 activate Nurr1, a key protein in brain health
- Activation helps protect dopamine neurons and improves movement
- The effect depends on Nurr1, confirming its central role
- These molecules may be natural regulators of Nurr1 function
- Findings support exploring PGE1/PGA1 as therapies